AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
GILD   77.83 (+3.33%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News

$44.51
-0.14 (-0.31 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$44.17
Now: $44.51
$45.68
50-Day Range
$32.63
MA: $40.14
$46.10
52-Week Range
$27.46
Now: $44.51
$51.35
Volume403,100 shs
Average Volume656,282 shs
Market Capitalization$1.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.
Read More
Pacira Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$421.03 million
Cash Flow$1.72 per share
Book Value$8.88 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Employees518
Market Cap$1.87 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions

How has Pacira Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PCRX shares have increased by 26.5% and is now trading at $44.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pacira Biosciences?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

When is Pacira Biosciences' next earnings date?

Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pacira Biosciences.

How were Pacira Biosciences' earnings last quarter?

Pacira Biosciences Inc (NASDAQ:PCRX) issued its earnings results on Thursday, May, 7th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.30 by $0.23. The business had revenue of $105.68 million for the quarter, compared to analysts' expectations of $101.64 million. Pacira Biosciences had a positive return on equity of 13.89% and a negative net margin of 0.02%. The company's quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.22 EPS. View Pacira Biosciences' earnings history.

What price target have analysts set for PCRX?

15 equities research analysts have issued 1-year price targets for Pacira Biosciences' stock. Their forecasts range from $41.00 to $85.00. On average, they anticipate Pacira Biosciences' share price to reach $54.50 in the next year. This suggests a possible upside of 22.4% from the stock's current price. View analysts' price targets for Pacira Biosciences.

Has Pacira Biosciences been receiving favorable news coverage?

Media stories about PCRX stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pacira Biosciences earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutPacira Biosciences.

Who are some of Pacira Biosciences' key competitors?

What other stocks do shareholders of Pacira Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Bausch Health Companies (BHC), Exelixis (EXEL), Micron Technology (MU), Incyte (INCY) and Neurocrine Biosciences (NBIX).

Who are Pacira Biosciences' key executives?

Pacira Biosciences' management team includes the following people:
  • Mr. David M. Stack, Chairman & CEO (Age 69)
  • Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)
  • Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)
  • Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53)

What is Pacira Biosciences' stock symbol?

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira Biosciences' major shareholders?

Pacira Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.35%), State Street Corp (3.33%), Spyglass Capital Management LLC (2.83%), Clearbridge Investments LLC (2.67%), Frontier Capital Management Co. LLC (2.57%) and Schroder Investment Management Group (1.94%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences.

Which major investors are selling Pacira Biosciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Two Sigma Investments LP, Schroder Investment Management Group, Nuveen Asset Management LLC, Maverick Capital Ltd., Maverick Capital Ltd., Two Sigma Advisers LP, and UBS Group AG. Company insiders that have sold Pacira Biosciences company stock in the last year include Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings, and Richard Scranton. View insider buying and selling activity for Pacira Biosciences.

Which major investors are buying Pacira Biosciences stock?

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Spyglass Capital Management LLC, Loomis Sayles & Co. L P, Rice Hall James & Associates LLC, State Street Corp, Russell Investments Group Ltd., Mesirow Financial Investment Management Equity Management, Granahan Investment Management Inc. MA, and Grantham Mayo Van Otterloo & Co. LLC. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences.

How do I buy shares of Pacira Biosciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pacira Biosciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $44.51.

How big of a company is Pacira Biosciences?

Pacira Biosciences has a market capitalization of $1.87 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.

What is Pacira Biosciences' official website?

The official website for Pacira Biosciences is www.pacira.com.

How can I contact Pacira Biosciences?

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.